Calculating the cost of medication errors: A systematic review of approaches and cost variables.

Cost-effectiveness Health policy Medical error, measurement/epidemiology Medication safety

Journal

BMJ open quality
ISSN: 2399-6641
Titre abrégé: BMJ Open Qual
Pays: England
ID NLM: 101710381

Informations de publication

Date de publication:
16 Apr 2024
Historique:
received: 20 08 2023
accepted: 24 03 2024
medline: 18 4 2024
pubmed: 17 4 2024
entrez: 16 4 2024
Statut: epublish

Résumé

Medication errors are an unnecessary cost to a healthcare system and patients of a country. This review aimed to systematically identify published cost variables used to calculate the cost of medication errors and to explore any updates on findings already known on calculating the cost of medication errors during the past 10 years. A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Electronic databases, PubMed, Scopus, Emerald and JSTOR were searched, using keywords "medication error" AND "cost" and predetermined inclusion criteria. Duplicate articles were removed. Quality check was done using 10 criteria. Cost variables used in calculating the cost of medication errors were extracted from each article. Among 3088 articles, 33 articles were selected for review. Most studies were conducted in Western countries. Cost variables used (types and number) by different studies varied widely. Most studies (N=29) had used direct costs only. A few studies (N=4) had used both direct and indirect costs for the purpose. Perspectives considered when calculating cost of medication errors also varied widely. A total of 35 variables used to calculate medication error costs were extracted from selected articles. Variables used to calculate the cost of medication errors were not uniform across studies. Almost a decade after systematic reviews previously reporting on this area, a validated methodology to calculate the cost of medication errors has still not been reported to date and highlights the still pending necessity of a standard method to be established.

Identifiants

pubmed: 38626938
pii: bmjoq-2023-002570
doi: 10.1136/bmjoq-2023-002570
pii:
doi:

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Am J Ther. 2016 Nov/Dec;23(6):e1307-e1314
pubmed: 26938748
Ren Fail. 2014 Sep;36(8):1268-72
pubmed: 24987790
Int J Clin Pharm. 2018 Jun;40(3):513-519
pubmed: 29603074
Jt Comm J Qual Patient Saf. 2012 Mar;38(3):120-6
pubmed: 22435229
Sr Care Pharm. 2019 Jun 1;34(6):384-392
pubmed: 31164185
BMC Cancer. 2011 Nov 08;11:478
pubmed: 22067636
Pharmacotherapy. 2014;34(4):350-7
pubmed: 24214289
Res Social Adm Pharm. 2016 May-Jun;12(3):428-37
pubmed: 26361821
Expert Rev Pharmacoecon Outcomes Res. 2020 Oct;20(5):481-490
pubmed: 31899986
Br J Clin Pharmacol. 2019 Sep;85(9):2155-2162
pubmed: 31219195
Pharmacoepidemiol Drug Saf. 2017 May;26(5):481-497
pubmed: 28295821
Br J Clin Pharmacol. 2009 Jun;67(6):599-604
pubmed: 19594526
PLoS One. 2017 Apr 26;12(4):e0174513
pubmed: 28445474
J Oncol Pharm Pract. 2022 Jul;28(5):1049-1055
pubmed: 34000918
Value Health. 2011 Jan;14(1):34-40
pubmed: 21211484
Ann Emerg Med. 2011 Sep;58(3):270-279.e4
pubmed: 21354651
Eur J Health Econ. 2018 Dec;19(9):1303-1318
pubmed: 29754324
Vaccine. 2012 Jun 6;30(26):3862-6
pubmed: 22521848
Pharmacoeconomics. 2020 Oct;38(10):1135-1145
pubmed: 32696192
Open Forum Infect Dis. 2019 Jun 24;6(7):ofz290
pubmed: 31338383
Medicine (Baltimore). 2017 Aug;96(34):e7883
pubmed: 28834903
Aten Primaria. 2021 Jan;53(1):43-50
pubmed: 32994060
Eur J Hosp Pharm. 2016 Sep;23(5):294-301
pubmed: 31156868
Bull World Health Organ. 2018 Mar 01;96(3):155-164
pubmed: 29531414
Jt Comm J Qual Patient Saf. 2020 Jan;46(1):3-10
pubmed: 31786147
AMA J Ethics. 2015 Nov 01;17(11):1046-52
pubmed: 26595246
Res Social Adm Pharm. 2022 Apr;18(4):2683-2690
pubmed: 34148853
Iran J Public Health. 2014 Feb;43(2):202-9
pubmed: 26060744
J Oncol Pharm Pract. 2013 Mar;19(1):8-17
pubmed: 22623276
Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):176-86
pubmed: 24934134
Am J Med. 2011 Dec;124(12):1136-42
pubmed: 22114827
Clin Rheumatol. 2011 Nov;30(11):1421-4
pubmed: 21947700
Appl Health Econ Health Policy. 2022 Jan;20(1):91-104
pubmed: 34403128

Auteurs

Sakunika Ranasinghe (S)

Pharmacy and Pharmaceutical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Abarna Nadeshkumar (A)

Pharmacy and Pharmaceutical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Savini Senadheera (S)

Pharmacy and Pharmaceutical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Nithushi Samaranayake (N)

Pharmacy and Pharmaceutical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka nithushi@sjp.ac.lk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH